Posts

Showing posts with the label Dengue Vaccines

Future Prospects of Global Laboratory Proficiency Testing Market

Image
Laboratory Proficiency Testing Market  The global Laboratory Proficiency Testing Market is estimated to be valued at US$ 1.29 billion in 2023 and is expected to exhibit a CAGR of 7.3% over the forecast period 2023 - 2030, as highlighted in a new report published by Coherent Market Insights. Market Overview: Laboratory proficiency testing involves evaluating the performance of laboratories for a given scope of testing through inter-laboratory comparisons. It helps assess the quality and competence of laboratories by determining reproducibility and accuracy of test results. Proficiency testing products are used by laboratories to determine method validity and accuracy, and improve testing processes. Market Key Trends: One of the major trends in the laboratory proficiency testing market is the growing number of accredited medical laboratories. Accreditation assures compliance with ISO 15189 and ISO/IEC 17025 standards, which require participation in proficiency testing programs. Acc...

Dengue Vaccine Market Overview, Drivers, Restraints and Opportunities

Image
Dengue fever, often known as breakbone fever, is a viral virus transmitted by mosquitos that causes a severe flu-like disease. Severe dengue fever is a potentially fatal consequence of the disease. Dengue vaccine is a human vaccine that prevents dengue disease. Global Dengue Vaccine Market: Drivers Over the forecast period, the worldwide dengue vaccine market is expected to rise due to rising dengue prevalence. According to the Pan American Health Organization, a total of 1,191,815 cases of dengue fever were recorded in the Americas region between epidemiological weeks 1 and 22 of 2019, with 546,589 cases being laboratory-confirmed and 5,599 being categorised as severe dengue. Furthermore, market expansion is likely to be aided by R&D of live attenuated vaccines. Dengvaxia, for example, was licenced by the US Food and Drug Administration in May 2019 for the prevention of dengue fever caused by all dengue virus serotypes. It's a chimaera vaccine developed with recombinant...

Dengue Vaccines Market: Drivers, Restraints and Opportunities

Image
Dengue fever, often known as breakbone fever, is a viral virus transmitted by mosquitos that causes a severe flu-like disease. Severe dengue fever is a potentially fatal consequence of the disease. Dengue vaccine is a human vaccine that prevents dengue disease. Dengue vaccine is only indicated for people who have experienced dengue fever before. It is administered in three injections over the course of a year.   Global Dengue Vaccine Market: Drivers Over the forecast period, the worldwide dengue vaccine market is expected to rise due to rising dengue prevalence. According to the Pan American Health Organization, a total of 1,191,815 dengue cases were recorded in the Americas region, with 546,589 being laboratory-confirmed and 5,599 being classed as severe dengue. Dengue Vaccines Market   Furthermore, market expansion is likely to be aided by R&D of live attenuated vaccines. Dengvaxia, for example, was licenced by the US Food and Drug Administration in May 2019 f...

Popular posts from this blog

Future Prospects of Global Laboratory Proficiency Testing Market

Malaria Vaccines Market – Making Way for a Malaria-Free World

Global and China Catheter Market Size, Share, Outlook, and Opportunity Analysis, 2020 - 2027